GRAL GRAIL Inc.

$GRAL the Galleri test found stage 1 in my dads lung. The front page of his results identified "lung" as abnormal...He had no symptoms and this test probably saved his life. After CT and biopsy it was confirmed. He had surgery 2 weeks ago and the removed the cancerous tissue. The doctors at UC Davis hadn't even heard of the test and were asking all about it and I guess the board of doctors had a meeting regarding my dads case and the Galleri test. Pretty amazing!!

$GRAL My connection to GRAIL started with taking the test, not buying the stock. About two years ago, as a Carpenters Union member, I was approved through our EAS Carpenters insurance to take GRAIL’s Galleri multi-cancer early detection test because of potential cancer exposures associated with jobsite conditions. I took the test, and it actually introduced me to GRAIL. After learning more about the company and its technology, I decided to invest around $22 a share. It’s interesting how something that started as a personal healthcare decision turned into an investment. As someone who works in construction, early cancer detection is something I genuinely care about. Just sharing my personal experience. #GRAL #GRAIL #Galleri

$GRAL “Detection at stage 3 or sooner is early”. Overwhelming majority of experts agree. I recall aome FDA panel members saying they need to define early on the label to add context if FDA decides to keep early on the label.

$GRAL larryr15, I’ve read that GRAL is presenting Six abstracts sometime between Oct 6-8 . So They may have already presented . As far as price action , remember how the news leaked out before the FDA advisory panel meeting ?

$GRAL (2) Data across both meetings will include: A rapid oral presentation highlighting the efficiency and safety of Cancer Signal Origin (CSO) guided diagnostic workups. A poster showing Galleri cancer detection of more than 200 cancers across histologically distinct cancer types, including rare cancers. A poster showing Galleri cancer detection performance and accuracy across self-reported racial and ethnic groups. A poster presenting new NHS-Galleri data on the preclinical window for cancer detection with findings compatible with annual MCED screening. A poster showing a reduction of cancer diagnoses in emergency presentations associated with annual Galleri screenings.

$GRAL I was just watching Fox News and they were talking about a company is coming out with a test for cancer and the blood called the Galleria test. It was on Fox News approximately five minutes ago.

$GRAL Selling some more, locking in some more profits at about 214% (pending reporting.) from 9-2025 Buy.

$GRAL What a terrific opprtunity to add shares now....short term profit taking is completed; getting ready for next big wave, bigger than before.

$GRAL With total madness, Cramer will be screaming Buy, Buy, Buy once he is fully loaded. FDA panel has been supportive of early detection (over 80% detected at or prior to stage 3 and over 50% at or prior to stage 2) for multiple cancers (example, pancreatic, liver, biliary, ovarian, etc) for which there is no screening available with 70% sensitivity and over 99.5% specificity. Over 19 out of 21 testimonials were passionate and in strong favor of approval. FDA label will NOT restrict its use in this arena. CMS coverage will follow rapidly. $20B market cap within 5 years is what is at stake here with additional emerging data from ongoing trials and post marketing surveillance.

$GRAL *Biotech *Multiple Cancer Detection (MCD) Testing Up another 7.6% today, with 10/11 Green Days with one halted day prior to the news... Only one down day so far on 10-01-26, last Thurs. At 154.98 GRAL is at about 85% vs the predicted short term trading Opportunity Range™ for today, so fairly stretched at this point in the day (100% being the top of the trading range).

$GRAL very interested in starting a position in this ticker. How long would it take for private insurance to start covering galleri? Would they have to wait until Medicare covers it (so at least a year after fda approval?)

$GRAL Latest company news, Oct 21, 2026: GRAIL will report Q3 2026 results after the market close on November 4, followed by a webcast at 4:30 p.m. ET. More details in our $GRAL stock hub. Not investment advice.

$GRAL — Galleri has an enormous potential market, but the regulatory details matter. GRAIL’s multi-cancer early detection blood test recently received a favorable FDA advisory-panel assessment on safety. The panel voted 6–4 in favor of effectiveness, reflecting both support for the technology and remaining questions about its clinical benefits. Galleri is designed to identify cancer-associated signals across multiple cancer types from a blood sample. The potential is significant, but FDA approval isn’t guaranteed, and questions about false positives and whether screening improves patient outcomes remain important.

$GRAL for anyone who is interested in Epidemiology. Please ask AI this question. What is Lead time bias and please give some examples of what lead time bias in cancer detection

$GRAL seems like their presentation in Spain on 10/25 & 10/26 was received well . Stock is up substantially yesterday and today. Volume is a little low as of 1:50 pm.

$GRAL Grail to Present Two Abstracts at the European Society for Medical Oncology Congress in Madrid, Spain on Oct. 25 & Oct. 26 2026 .

$GRAL watch. FDA should announce approval soon! Keep buying. Quick. Have a great buying day. Don’t miss the boat.

📅 CATALYST REMINDER | $GRAL October 25–26, 2026 — Cancer Detection Data October 25: Galleri diagnostic-workup poster after positive multicancer early detection tests. October 26: PATHFINDER 2 data on cancer-signal-origin-guided diagnostic workups at ESMO. More details in our hub. #GRAL #Biotech #ESMO2026

$GRAL anyone know exactly when this data is coming? Is it likely to move the stock higher?

$GRAL was looking to get my toes wet in this but too cold at the moment lemme know when coast is clear